Advertisement

Topics

"Responsible pricing" by Pfizer allows NICE to back use of Vizimpro as first-line treatment in NSCLC https://www.firstwordpharma.com/node/1651467  $PFE

06:28 EDT 5 Jul 2019 | FirstWord Pharma

"Responsible pricing" by Pfizer allows NICE to back use of Vizimpro as first-line treatment in NSCLC https://www.firstwordpharma.com/node/1651467 

Original Article: "Responsible pricing" by Pfizer allows NICE to back use of Vizimpro as first-line treatment in NSCLC https://www.firstwordpharma.com/node/1651467  $PFE

NEXT ARTICLE

More From BioPortfolio on ""Responsible pricing" by Pfizer allows NICE to back use of Vizimpro as first-line treatment in NSCLC https://www.firstwordpharma.com/node/1651467  $PFE"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...